Triple-negative breast cancer (TNBC) presents a significant challenge in oncology due to its aggressive nature and limited targeted therapeutic options. This study explores the potential of autocrine motility factor (AMF) and an AMF-derived peptide as novel treatments for TNBC. AMF, primarily secreted by neoplastic cells, plays a crucial role in cancer cell motility, metastasis, and proliferation. The research demonstrates that AMF and its derived peptide inhibit TNBC cell proliferation by modulating cellular migration, redox homeostasis, apoptotic pathways, and drug efflux mechanisms. Dose-dependent antiproliferative effects were observed across three TNBC cell lines, with higher concentrations impairing cellular migration. Mechanistic studies revealed decreased glucose-6-phosphate dehydrogenase expression and elevated reactive oxygen species production, suggesting redox imbalance as a primary mediator of apoptosis. Combination studies with conventional therapeutics showed near-complete eradication of resistant TNBC cells. The observed reduction in p53 levels and increased intranuclear doxorubicin accumulation highlight the AMF/AMF peptide’s potential as multidrug resistance modulators. This study underscores the promise of using AMF/AMF peptide as a novel therapeutic approach for TNBC, addressing current treatment limitations and warranting further investigation.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, driven by chemoresistance and metabolic reprogramming centered on glucose-6-phosphate dehydrogenase (G6PD)-dependent pentose phosphate pathway activity. Exogenously administered autocrine motility factor (AMF) suppresses G6PD at transcriptional and protein levels, elevating intracellular reactive oxygen species (ROS) to cytostatic thresholds. Glycyrrhetinic acid (GA), a bioactive triterpenoid from licorice root, amplifies oxidative stress through mitochondrial membrane disruption, while concurrently downregulating multidrug resistance-associated ABC transporters. Three PDAC cell lines were treated with AMF variants and GA. Cell viability was assessed by MTT assay and clonogenic survival assays. Mechanistic endpoints included DCFDA fluorescence, Western blotting, RT-qPCR, and doxorubicin/Hoechst 33342 fluorescence for drug retention analysis. Among eight distinct AMF variants, HG-AMF demonstrated the greatest cytotoxic potency both alone and in combination with GA. HG-AMF suppressed G6PD mRNA and protein expression, inducing sustained ROS accumulation confirmed by DCFDA fluorescence. Co-treatment with GA produced enhanced ROS generation, clonogenic suppression, decreased mitochondrial membrane potential, and impaired drug efflux. HG-AMF and GA converge on G6PD-dependent metabolism and chemoresistance pathways, providing a rational basis for their combined application in PDAC therapy.
Skin hyperpigmentation caused by excessive melanin production has led to increasing interest in the development of effective anti-melanogenic agents. In this study, the anti-melanogenic effects and underlying mechanisms of nicotinamide mononucleotide (NMN) were investigated using α-MSH-induced B16F10 melanoma cells. NMN maintained over 80% cell viability at concentrations below 0.5% and significantly reduced α-MSH-induced melanin accumulation and melanin content. In addition, in situ tyrosinase assay demonstrated that NMN effectively suppressed intracellular melanogenesis. However, NMN did not exhibit direct inhibitory activity against mushroom tyrosinase. Molecular docking analysis further revealed that NMN did not directly interact with the catalytic copper-binding site of tyrosinase. Furthermore, tyrosinase zymography and Western blot analyses demonstrated that NMN suppressed melanogenesis primarily through downregulation of tyrosinase protein expression rather than direct inhibition of tyrosinase catalytic activity. Collectively, these findings suggest that NMN suppresses melanogenesis through regulation of melanogenic signaling pathways, indicating its potential utility for hyperpigmentation-related applications.
The journal retracts the article titled “Autocrine Motility Factor and Its Peptide Derivative Inhibit Triple-Negative Breast Cancer by Regulating Wound Repair, Survival, and Drug Efflux”